Loading clinical trials...

SCN2A Polymorphisms Are Associated With Response to Valproic Acid in Paediatric Population(Pakistan) | Clinical Trials | Clareo Health

COMPLETED

SCN2A Polymorphisms Are Associated With Response to Valproic Acid in Paediatric Population(Pakistan)

SCN2A, rs2304016 Polymorphisms Are Associated With Response to Valproic Acid in Paediatric Epilepsy Patients (Pakistan)

NCT06674070•Riphah International University

View on ClinicalTrials.gov

Summary

The goal of this Observational study was to identify the effect of SCN2A gene polymorphism in the Paediatric epileptic Pakistani population. The main question it aims to answer is: to evaluate the effect of this genetic polymorphism on the clinical efficacy of Valproic acid Participants were prescribed Valproic acid after diagnosis of epilepsy.

Detailed Description

This observational study aimed to identify the effect of SCN2A rs2304016 gene polymorphism in the Paediatric epileptic population. The main question it aims to answer is: • to evaluate the effect of this genetic polymorphism on the clinical efficacy of Valproic acid The participants' blood samples were taken and further genotyping was performed using conventional tetraARMS PCR. The results were visualized by gel electrophoresis.

Eligibility

Age

0 - 12 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Epileptic Pakistani individuals of age between 1 to 12 years of either sex
•Each patient had experienced two or more clinically confirmed, spontaneous epileptic seizures in the past.
•Newly diagnosed patients started VPA 20 mg/kg (drug of the same brand was used for every patient throughout the study).

Exclusion Criteria

•Patients taking any other anti-epileptic drug.
•Patients taking medications that interact with VPA.
•Patients with moderate or severe systemic diseases

Locations (1)

IIMC, Riphah International University

Islamabad, Federal, Pakistan

Key Dates

Start Date

December 1, 2023

Primary Completion Date

July 31, 2024

Completion Date

August 31, 2024

Last Updated

November 5, 2024

Enrollment

200

ACTUAL participants

Conditions

Epilepsy

Interventions

Valproic Acid

GENETIC

Thalamus Seizure Detection With a Deep Brain Stimulator System

NCT06700356

Epilepsy; Seizure

View study

RECRUITINGPHASE1

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

NCT02531880

Epilepsy

View study

RECRUITINGNA

Intracranial Investigation of Neural Circuity Underlying Human Mood

NCT05871372

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 5, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

SCN2A Polymorphisms Are Associated With Response to Valproic Acid in Paediatric Population(Pakistan)

Inclusion Criteria

Exclusion Criteria

Thalamus Seizure Detection With a Deep Brain Stimulator System

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

Intracranial Investigation of Neural Circuity Underlying Human Mood

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

Late-Onset Seizures: Trial of Vascular Risk Investigation and Treatment

MEHMO Natural History and Biomarkers